4563 On Other Exchanges
4563 is not on other exchanges.

anges mg inc (4563) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ANGES MG INC (4563)

Related News

No related news articles were found.

anges mg inc (4563) Related Businessweek News

No Related Businessweek News Found

anges mg inc (4563) Details

AnGes MG, Inc., a biopharmaceutical company, engages in the research and development, manufacture, and marketing of genetic medicines and medical devices. The company’s marketed product is Naglazyme, a drug for the treatment of mucopolysaccharidosis VI, an intractable disease. It is also developing hepatocyte growth factor plasmid, a gene therapy in the last stage of clinical development for the treatment of critical limb ischemia, which is a serious impairment of blood circulation in the legs. In addition, the company engages in the research and development of pharmaceutical products based on NFkB Decoy Oligonucleotide, a nucleic-acid medicine for the treatment of immune and inflammatory diseases, such as atopic dermatitis, PTA balloon catheter, and disc degeneration; and cervical intraepithelial neoplasia (CIN) and DNA therapeutic vaccines, as well as Allovectin, a cancer treatment drug. It has alliances with BioLeaders Corporation to develop, manufacture, use, and market CIN vaccine in China; BioMarin Pharmaceutical Inc. to market a drug for the treatment of mucopolysaccharidosis VI; Hosokawa Micron Corporation for the technology development of poly lactic-co-glycolic acid particle preparations containing NF-kB decoy oligonucleotide; Medikit Co., Ltd. to develop, manufacture, and market percutaneous transluminal angioplasty medical device; Mitsubishi Tanabe Pharma Corporation for the treatment of peripheral arterial disease in the United States and japan; SHIONOGI & CO., LTD. for the marketing of drugs for external use containing NF-kB decoy oligonucleotide for the indication of skin diseases; and Vical, Inc. for the development and marketing of Allovectin. The company was formerly known as MedGene Bioscience Co., Ltd. and changed its name to AnGes MG, Inc. in October 2001. AnGes MG, Inc. was founded in 1999 and is headquartered in Ibaraki, Japan.

55 Employees
Last Reported Date: 03/31/17
Founded in 1999

anges mg inc (4563) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

anges mg inc
AnGes MG, Inc. to Report Q1, 2017 Results on Apr 24, 2017

AnGes MG, Inc. announced that they will report Q1, 2017 results on Apr 24, 2017

Vical Incorporated Enters into Research Collaboration Agreement with AnGes MG, Inc

On April 4, 2017, Vical Incorporated entered into a research collaboration agreement with AnGes MG, Inc. Pursuant to the collaboration agreement, AnGes agreed to provide funding for the program up to a specified limit and Vical agreed to conduct certain preclinical research related to a development program targeting chronic hepatitis B. In exchange for the payment, AnGes will receive an option to negotiate exclusive rights in Japan related to the program. The parties also agreed to share the costs of prosecuting and maintaining intellectual property rights arising from the research program after such costs reach a specified limit.

AnGes MG, Inc. Proposes Amendments to Its Articles of Incorporation

AnGes MG, Inc. at its AGM to be held on March 30, 2017 proposed amendments to its articles of incorporation.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4563 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4563.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4563 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 36.3x
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 35.4x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ANGES MG INC, please visit www.anges-mg.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.